Prediction of "hot spots" of aggregation in disease-linked polypeptides

BMC Structural Biology

Volumn 5, Issue , 2005, Pages

  De Groot, Natalia Sánchez ^a   Pallarés, Irantzu ^a   Avilés, Francesc X ^a   Vendrell, Josep ^a   Ventura, Salvador ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ARTICLE; GENE MUTATION; LITERATURE; MODEL; PROTEIN AGGREGATION;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BETA 2-MICROGLOBULIN; HUMANS; INSULIN; MODELS, MOLECULAR; MURAMIDASE; MUTATION; NEURODEGENERATIVE DISEASES; PEPTIDES; PREALBUMIN; PRIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 26844546357     PISSN: 14726807     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-5-18     Document Type: Article

References (77)

1. Smith A: protein misfolding. Nature 2003, 426:883-883.
2. Rochet JC, Lansbury PT Jr: Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000, 10:60-68.
3. Uversky VN, Fink AL: Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 2004, 1698:131-153.
4. Kelly JW: The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998, 8:101-106.
5. Ventura S, Zurdo J, Narayanan S, Parreno M, Mangues R, Reif B, Chiti F, Giannoni E, Dobson CM, Aviles FX, Serrano L: Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A 2004, 101:7258-7263.
6. Ivanova MI, Sawaya MR, Gingery M, Attinger A, Eisenberg D: An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. Proc Natl Acad Sci U S A 2004, 101:10584-10589.
7. Dobson CM: Protein misfolding, evolution and disease. Trends Biochem Sci 1999, 24:329-332.
8. Linding R, Schymkowitz J, Rousseau F, Diella F, Serrano L: A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J Mol Biol 2004, 342:345-353.
9. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L: Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004, 22:1302-1306.
10. de Groot N, Aviles FX, Vendrell J, Ventura S: 2005. Submitted
11. Bitan G, Vollers SS, Teplow DB: Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003, 278:34882-34889.
12. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM: Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003, 424:805-808.
13. Fink AL: Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des 1998, 3:R9-23.
14. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM: Prediction of "Aggregation-prone" and "Aggregation- susceptible" Regions in Proteins Associated with Neurodegenerative Diseases. J Mol Biol 2005, 350:379-392.
15. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
16. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J: Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 2004, 25:663-674.
17. Williams AD, Portelius E, Kheterpal I, Guo JT, Cook KD, Xu Y, Wetzel R: Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 2004, 335:833-842.
18. Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, Nagao M, Fukuda H, Shimizu T, Shirasawa T: Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol Chem 2004, 279:52781-52788.
19. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R: A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 2002, 99:16742-16747.
20. Torok M, Milton S, Kayed R, Wu P, McIntire T, Glabe CG, Langen R: Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 2002, 277:40810-40815.
21. Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, Dyda F, Reed J, Tycko R: Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR. Biochemistry 2000, 39:13748-13759.
22. Findeis MA, Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, Lee JJ, Chin J, Kelley M, Wakefield J, Hayward NJ, Molineaux SM: Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 1999, 38:6791-6800.
23. Jarrett JT, Berger EP, Lansbury PT Jr: The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
24. Yamamoto N, Hasegawa K, Matsuzaki K, Naiki H, Yanagisawa K: Environment- and mutation-dependent aggregation behavior of Alzheimer amyloid beta-protein. J Neurochem 2004, 90:62-9.
25. Wurth C, Guimard NK, Hecht MH: Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. J Mol Biol 2002, 319:1279-1290.
26. Clark A, Cooper GJ, Lewis CE, Morris JF, Willis AC, Reid KB, Turner RC: Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987, 2:231-234.
27. Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, Muller SA, Kistler J, Cooper GJ, Aebi U: Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol 2000, 130:352-362.
28. Kajava AV, Aebi U, Steven AC: The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. J Mol Biol 2005, 348:247-252.
29. Scrocchi LA, Ha K, Chen Y, Wu L, Wang F, Fraser PE: Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis. J Struct Biol 2003, 141:218-27.
30. Tracz SM, Abedini A, Driscoll M, Raleigh DP: Role of aromatic interactions in amyloid formation by peptides derived from human Amylin. Biochemistry 2004, 43:15901-15908.
31. Moriarty DF, Raleigh DP: Effects of sequential proline substitutions on amyloid formation by human amylin 20-29. Biochemistry 1999, 38:1811-1818.
32. Azriel R, Gazit E: Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J Biol Chem 2001, 276:34156-34161.
33. Green J, Goldsbury C, Mini T, Sunderji S, Frey P, Kistler J, Cooper G, Aebi U: Full-length rat amylin forms fibrils following substitution of single residues from human amylin. J Mol Biol 2003, 326:1147-1156.
34. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K: Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996, 45:1279-1281.
35. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes 1989, 38:1333-1336.
36. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
37. Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001, 2:492-501.
38. Bodles AM, Guthrie DJ, Greer B, Irvine GB: Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J Neurochem 2001, 78:384-395.
39. Giasson BI, Murray IV, Trojanowski JQ, Lee VM: A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001, 276:2380-2386.
40. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M: Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002, 277:19213-10219.
41. Der-Sarkissian A, Jao CC, Chen J, Langen R: Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J Biol Chem 2003, 278:37530-37535.
42. Choi W, Zibaee S, Jakes R, Serpell LC, Davletov B, Crowther RA, Goedert M: Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett 2004, 576:363-8.
43. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
44. Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP: Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 2004, 117:1017-1024.
45. Huang Y, Cheung L, Rowe D, Halliday G: Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 2004, 46:44-70.
46. Koch KM: Dialysis-related amyloidosis. Kidney Int 1992, 41:1416-1429.
47. McParland VJ, Kad NM, Kalverda AP, Brown A, Kirwin-Jones P, Hunter MG, Sunde M, Radford SE: Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry 2000, 39:8735-8746.
48. Kozhukh GV, Hagihara Y, Kawakami T, Hasegawa K, Naiki H, Goto Y: Investigation of a peptide responsible for amyloid fibril formation of beta 2-microglobulin by achromobacter protease I. J Biol Chem 2002, 277:1310-1315.
49. Hasegawa K, Ohhashi Y, Yamaguchi I, Takahashi N, Tsutsumi S, Goto Y, Gejyo F, Naiki H: Amyloidogenic synthetic peptides of beta2-microglobulin-a role of the disulfide bond. Biochem Biophys Res Commun 2003, 304:101-106.
50. Jones S, Manning J, Kad NM, Radford SE: Amyloid-forming peptides from beta2-microglobulin-Insights into the mechanism of fibril formation in vitro. J Mol Biol 2003, 325:249-57.
51. Ivanova MI, Gingery M, Whitson LJ, Eisenberg D: Role of the C-terminal 28 residues of beta2-microglobulin in amyloid fibril formation. Biochemistry 2003, 42:13536-13540.
52. Bellotti V, Stoppini M, Mangione P, Sunde M, Robinson C, Asti L, Brancaccio D, Ferri G: Beta2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. Eur J Biochem 1998, 258:61-67.
53. Ivanova MI, Sawaya MR, Gingery M, Attinger A, Eisenberg D: An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. Proc Natl Acad Sci U S A 2004, 101:10584-10589.
54. Yamamoto S, Hasegawa K, Yamaguchi I, Tsutsumi S, Kardos J, Goto Y, Gejyo F, Naiki H: Low concentrations of sodium dodecyl sulfate induce the extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 2004, 43:11075-11082.
55. Kihara M, Chatani E, Sakai M, Hasegawa K, Naiki H, Goto Y: Seeding-dependent maturation of beta2-microglobulin amyloid fibrils at neutral pH. J Biol Chem 2005, 280:12012-12018.
56. Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CCF, Terry CJ, Feest TG, Zalin AM, Hsuan JJ: Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993, 362:553-557.
57. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB: Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997, 385:787-793.
58. Canet D, Last AM, Tito P, Sunde M, Spencer A, Archer DB, Redfield C, Robinson CV, Dobson CM: Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat Struct Biol 2002, 9:308-315.
59. Yang JJ, Buck M, Pitkeathly M, Kotik M, Haynie DT, Dobson CM, Radford SE: Conformational properties of four peptides spanning the sequence of hen lysozyme. J Mol Biol 1995, 29:483-491.
60. Krebs MR, Wilkins DK, Chung EW, Pitkeathly MC, Chamberlain AK, Zurdo J, Robinson CV, Dobson CM: Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the beta-domain. J Mol Biol 2000, 300:541-549.
61. Frare E, Polverino De Laureto P, Zurdo J, Dobson CM, Fontana A: A highly amyloidogenic region of hen lysozyme. J Mol Biol 2004, 340:1153-1165.
62. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J: Prediction of amyloid fibril-forming proteins. J Biol Chem 2001, 276:12945-12950.
63. Saraiva MJ, Birken S, Costa PP, Goodman DS: Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984, 74:104-119.
64. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W: Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995, 34:13527-13536.
65. Hornberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE: A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 2000, 22:649-669.
66. Richardson JS, Richardson DC: Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc Natl Acad Sci U S A 2002, 99:2754-2759.
67. Jaroniec CP, MacPhee CE, Astrof NS, Dobson CM, Griffin RG: Molecular conformation of a peptide fragment of transthyretin in an amyloid fibril. Proc Natl Acad Sci U S A 2002, 99:16748-16753.
68. Jaroniec CP, MacPhee CE, Bajaj VS, McMahon MT, Dobson CM, Griffin RG: High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc Natl Acad Sci U S A 2004, 101:711-716.
69. Jarvis JA, Kirkpatrick A, Craik DJ: 1H NMR analysis of fibril-forming peptide fragments of transthyretin. Int J Pept Protein Res 1994, 44:388-39.
70. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE: Prion protein biology. Cell 1998, 93:337-348.
71. Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolai L, Wider G, Wuthrich K: NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 2000, 97:145-150.
72. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, Cohen FE, Prusiner SB: Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A 1997, 94:10069-10074.
73. Tagliavini F, Prelli F, Verga L, Giaccone G, Sarma R, Gorevic P, Ghetti B, Passerini F, Ghibaudi E, Forloni G, Salmona M, Bugiani O, Frangione B: Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A 1993, 90:9678-9682.
74. Gu Y, Fujioka H, Mishra RS, Li R, Singh N: Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 2002, 277:2275-86.
75. Chabry J, Ratsimanohatra C, Sponne I, Elena PP, Vincent JP, Pillot T: In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression. J Neurosci 2003, 23:462-469.
76. Santini S, Wei G, Mousseau N, Derreumaux P: Pathway complexity of Alzheimer's beta-amyloid Abeta16-22 peptide assembly. Structure 2004, 12:1245-1255.
77. Haspel N, Zanuy D, Ma B, Wolfson H, Nussinov R: A comparative study of amyloid fibril formation by residues 15-19 of the human calcitonin hormone: a single beta-sheet model with a small hydrophobic core. J Mol Biol 2005, 345:1213-1227.